Janssen-Cilag International NV, of Beerse, Belgium, part of Johnson & Johnson, said the EMA's Committee for Medicinal Products for Human Use adopted a positive opinion recommending the approval of Velcade (bortezomib), in combination with Rituxan (rituximab, Biogen Idec Inc. and Roche AG), cyclophosphamide, doxorubicin and prednisone, for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for hematopoietic stem cell transplantation.